Loxapine (Adasuve) vs Olanzapine (Zyprexa Relprevv)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Reported efficacy
Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)
Result source: NCT00628589
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Loxapine (Adasuve) | Olanzapine (Zyprexa Relprevv) |
|---|---|---|
| PANSS total, change | —Not reported | —Not posted · NCT00088491 |
| CGI-S, change | —Not reported | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 |
| PANSS response | —Not reported | —Not posted · NCT00088491 |
| PSP, change | —Not reported | —Not posted · NCT00088491 |
| Relapse (% of patients) | —Not reported | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 |
PANSS total, change
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
CGI-S, change
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
PANSS response
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
PSP, change
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
Relapse (% of patients)
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Loxapine (Adasuve): 3 of 4 rows · Olanzapine (Zyprexa Relprevv): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Loxapine (Adasuve) | Olanzapine (Zyprexa Relprevv) |
|---|---|---|
| Dropout rate | 2.7%10 mga NCT00628589 · Phase 3 · monotherapy show 8 more results1.7%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence | 54.9%a NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mga NCT00628589 · Phase 3 · monotherapy show 8 more results—5 mg NCT00628589 · Phase 3 · monotherapy —10 mg NCT00369577 · Phase 2 · registry result, not featured evidence —5 mg NCT00369577 · Phase 2 · registry result, not featured evidence —10 mg NCT00444028 · Phase 1 · registry result, not featured evidence —5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence —0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence | 9.8%a NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0.9%10 mga NCT00628589 · Phase 3 · monotherapy show 8 more results0%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 2.2%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence | 9.5%a NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mga dizziness 10.6% (placebo 9.6%) dysgeusia 10.6% (placebo 2.6%) sedation 10.6% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy show 8 more results5 mg sedation 12.9% (placebo 9.6%) dysgeusia 8.6% (placebo 2.6%) dizziness 5.2% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy 10 mg sedation 22% (placebo 14%) dysgeusia 17.1% (placebo 9.3%) headache 12.2% (placebo 2.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 5 mg sedation 13.3% (placebo 14%) dizziness 11.1% (placebo 9.3%) dysgeusia 4.4% (placebo 9.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 10 mg dizziness 75% (placebo 35.7%) dysgeusia 75% (placebo 0%) somnolence 75% (placebo 21.4%) NCT00444028 · Phase 1 · registry result, not featured evidence 5 mg dizziness 57.1% (placebo 35.7%) fatigue 42.9% (placebo 7.1%) dysgeusia 28.6% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 2.5 mg dizziness 50% (placebo 35.7%) nausea 50% (placebo 0%) dysgeusia 33.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 1.25 mg dizziness 25% (placebo 35.7%) dysgeusia 25% (placebo 0%) headache 25% (placebo 14.3%) NCT00444028 · Phase 1 · registry result, not featured evidence 0.625 mg dizziness 28.6% (placebo 35.7%) disturbance in attention 14.3% (placebo 7.1%) dysgeusia 14.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Loxapine (Adasuve)
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Olanzapine (Zyprexa Relprevv)
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Olanzapine (Zyprexa Relprevv)'s landscape